EANS-News: Epigenomics AG: Study Shows Patient Preference for Blood Based Colorectal Cancer Screening

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/New Products/molecular diagnostics

Berlin, Germany, and Seattle, WA, U.S.A., March 6, 2012 (euro adhoc)
- Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American
cancer molecular diagnostics company, today announced that results of
a survey on colorectal cancer (CRC) screening preferences conducted
by Jennifer Taber et al. (Department of Psychology University of
Utah, Huntsman Cancer Institute, ARUP Laboratories) were presented at
the American Society for Preventive Oncology 2012 Annual Meeting in
Washington, DC on March 5, 2012.

The study assessed the attitudes and preferences of 100 participants
eligible for CRC screening of which 44% were previously unscreened,
with respect to screening by FOBT, sigmoidoscopy, colonoscopy or
Septin9 blood testing. In this focus group study, participants
completed a survey after a 90 minute moderated discussion about the
procedure, cost and accuracy of all tests.

The survey indicated that given the performance of the ARUP Septin9
test (90% sensitive, 89% specific; Warren et al. 2011) and its cost
of approximately USD 180, two thirds of previously unscreened
subjects would prefer a Septin9 blood test to other screening
methods. Among the positive aspects of the test, participants noted
its convenience (62%), cost (52%) and accuracy (55%). Among the
negative factors of the test, participants mentioned the inability to
detect precancerous polyps (6%) and lack of insurance coverage (6%).

Noel Doheny, CEO of Epigenomics' US subsidiary and member of the
Epigenomics Senior Management Team noted: "The study demonstrates
that the convenience of a blood based test should lead to a greater
acceptance and thus a higher compliance to colorectal cancer
screening. It underlines the value that blood-based Septin9 tests can
potentially bring as alternative for the detection of colorectal
cancer".

Karen Heichman, Ph.D., VP Oncology Technology Development &
Licensing, ARUP Laboratories added: "ARUP is proud to provide a
non-invasive blood based approach that people can use for the early
detection of colorectal cancer".

- Ends -

Further Information

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English